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The classical pathway of compkment is required for the adherence of soluble tetanus toxoid (TT)-human 
anti-TT complexes to erythrocytes. Using human G&deficient serum we compared the capacity of the two 
forms of human C4 (C4A and C4B) to mediate this function: C4A was shown to be 1.5-fold more efficient 
than C4B. In contrast, haemolysis by C4B was 3.7-fold more efficient than by C4A. Such large differences 
suggest hat both forms are complementary, and that C4A is preferentially involved in the processing of 
immune complexes in humans. 
Immune complex disease; C4 
At the time of complement activation, the C4 
molecule will interact with at least 8 other proteins 
which determine C4 activation, covalent C4b 
binding, formation of the classical pathway C3 
and CS convertases and their inactivation [l]. 
Variations in the structure of C4 are likely to affect 
one or another of these steps, and differences in 
the haemol~ic activity of various 0% alleles have 
been observed [2-s] _ The two forms of human C4, 
C4A and C4B, have different reactivity with sheep 
erythrocytes and also with insoluble immune com- 
pfexes (IC) [4,5]. Upon C4 activation, the intra- 
chain thiol ester bond of nascent C4b becomes 
available for reaction with acceptor sites present 
on proteins and cell surfaces; C4B binds to accep- 
tor hydroxyl groups more efficiently than C4A, 
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which in contrast reacts better with amino groups; 
these findings explain that C4B is several fold more 
efficient in haemolytic assays (hydroxyl groups 
predominate on erythrocytes) [6,7]. C4A is, 
however, not a ‘lesser C4’ since it binds to insolu- 
ble IC and mediates inhibition of immune 
precipitation better than C4B [5]. Here we in- 
vestigate the role of the 2 forms of C4 in their 
capacity to promote adherence of IC to 
erytbrocytes. 
2, MATERIALS AND ETHYLS 
The immune adherence assay was performed as 
foIlows: preformed soluble tetanus toxoid 
(TT)-human anti-TT complexes made in antibody 
excess (20 x equivalence) containing 64 ng TT 
were incubated at 37°C with 25 /cl serum; aliquots 
were removed after various intervals of time and 
added to 100~1 of a 25% suspension of human 
erythrocytes in 10 mM sodium phosphate, 
145 mM NaCl, pH 7-5 (PBS). After incubation for 
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10 min at 4”C, 1 ml cold PBS was added, and the 
percentage binding of IC to erythrocytes was deter- 
mined from the pellets and supernatants recovered 
after centrifugation at 400 x g for 3 min at 4°C. 
When measuring C4 function, the sera or proteins 
were added in percentage of the 25 ,ul of 
C4-deficient serum used in the assay. 
The following sera were used: (i) human C2- and 
C4-deficient sera; (ii) serum of a patient with 
nephritic factor containing <5% C3; (iii) serum 
from a patient with paraproteinaemia nd classical 
pathway depletion containing <25% Cl subcom- 
ponents and C2, undetectable haemolytic C4, but 
normal C3; (iv) normal and C4 deficient guinea- 
pig (GP) sera. 
.-- .-*.... -----_____ Cqdef ~~~~~..~~.~~-----~-----. 
8 I I 
C4 was purified as described [8] and, when re- 0 5 15 30 
quired, was inactivated with methylamine [9]. Time (min) 
Haemolytic C4 was measured according to 
Gaither et al. [lo], and antigenic C4 by single 
radial immunodiffusion using monospecific an- 
tiserum [5]. 
C4 phenotypes in different normal sera were 
defined as described by Awdeh and Alper [2]. 
Fig. 1. Binding of TT-anti-TT complexes to erythrocytes 
after various intervals of time in NHS, in human 
C4-deficient serum, and in this serum repleted with 1% 
or 5% purified C4. 
3. RESULTS 
In normal human serum (NHS) complement 
mediated the adherence of TT-anti-TT complexes 
to human erythrocytes (fig.1). This reaction was 
rapid, maximal in 5 min, and required C3 and 
classical pathway function: no adherence was 
observed in the Nef-containing serum, C2- and 
C4-deficient sera, and classical pathway-depleted 
serum. Using normal and CCdeficient GP sera 
provided similar results. In human and GP 
CCdeficient sera, the addition of small concentra- 
tions (1 Vo) of purified human C4 were sufficient to 
normalize this function (fig. 1). Inactivation of C4 
with methylamine abolished the binding. 
the assay 25 ~1 human CCdeficient serum. C4 
titration in NHS is shown in fig.2, and we ar- 
bitrarily defined ‘functional CCbinding units’ as 
the inverse of the concentration of serum required 
to produce 50% of the maximum binding (incuba- 
,O1 
50% of max,m"m DIndIng 
Adding 1% (0.25 ~1) of NHS to CCdeficient 
sera nearly normalized the reaction as well - this 
amount of NHS produced no IC adherence on its 
own. That the limiting factor in 1% NHS was C4 
was shown by re-establishing adherence with 1% 
of C2-deficient serum, Nef-containing serum, and 
normal GP serum, but not by GP CCdeficient 
serum and the human classical pathway-depleted 
serum. 
I 1 
'l/2404 = 2404 U/ml 
0 r ,I I 
\ I I 
1/64W l/3200 l/1600 l/800 l/W l/40 
0.015625 0.03125 0.0625 0.125 0.25% 2.5% 
Thus, the immune adherence assay could be 
used to titrate C4 function in various sera using in 
Fig.2. Adherence of TT-anti-TT complexes to 
erythrocytes after an incubation of 5 min with human 
CCdeficient serum supplemented with various dilutions 
of NHS. Functional C4-binding units in NHS were 
defined from the inverse of the dilution of the serum 
which restore 50% of the maximum adherence. 
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Table 1 
C4 measurements 
Sera Phenotypes Haemolytic Binding Ratio 
activity activity haemolyticl 
(U1.g) (U/& binding 
activity 
JS A2A3 BlB2 90 6.3 14.3 
C A3 BQO 42.1 7.0 6.0 
D A3 BQO 50.3 8.6 5.9 
S AQO BiB2 169 5.2 32.5 
A AQO Bl 203 5.1 39.8 
N AQO Bl 144 5.0 28.8 
tion time, 5 min). Normal human sera containing 
homozygous C4 null alleles were tested in this 
assay, and their functional C4-binding units were 
expressed per pg C4 (U/pg) (table 1): C4A was ap- 
prox. I..%fold more efficient than C4B. In con- 
trast, haemolysis by C4B was 3.7-fold more 
efficient than by C4A, so that the ratio of the two 
functions differed more than S&fold for the two 
forms of C4. 
4. DISCUSSION 
Here we demonstrate that human C4A and C4B 
differ in their capacity to mediate immune 
adherence of soluble IC, and this observation is 
made in a system involving only human reagents -
cells, antibodies, and complement source. The 
more efficient activity of C4A in this immune 
adherence assay corresponds to its more efficient 
binding to insoluble IC 131 and capacity to inhibit 
the precipitation of IC made with rabbit antibodies 
[5]. Thus, C4A is not a lesser form of C4, and is 
involved preferenti~ly in the processing of IC. 
In primates, the complement-mediated transport 
system for IC on erythrocytes has been shown to 
prevent IC deposition in various organs outside the 
fixed phagocytic system 1111. The immune 
adherence function of C4 described here is 
probably not limiting in the blood stream, since 
1% C4 was sufficient; however, C4 could become 
limiting in extravascular spaces where complement 
protein concentrations are low, and where C3b 
binding to IC could be necessary for efficient 
recognition by phagocytic cells and those involved 
in the immune response; for instance, B ceil 
memory has been shown to be defective in 
C3-depleted and C4- and CZdeficient animals 
[12,13]. It has been postulated that deficient C4 
function is involved in the pathogenesis of autoim- 
mune disease [1,14], a suggestion particularly 
entertained in patients with total C4 deficiency 
since most suffer from an SLE-like disease [15]. 
But are there any data on human diseases that sug- 
gest a different role for C4A and C4B? Four dif- 
ferent studies indicate that homozygous C4A null 
alleles (but not homozygous C4B null alleles) are 
found more frequently in patients with SLE than 
in normal controls [16-191. These observations 
would correlate with our in vitro findings: the 
absence of C4A - reacting preferentially with IC - 
may predispose to defective IC elimination. 
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